---

<< Back to listing

Interleukin Genetics Extends Invitation to Attend Analyst and Investor Luncheon Conference in New York City on Tuesday June 12, 2007

AN INVITATION TO

Interleukin Genetics, Inc. (AMEX: ILI)
Analyst and Investor Meeting In New York City

Tuesday, June 12th, 2007
12:00 p.m. – 2:00 p.m.

The Waldorf Astoria
301 Park Ave, New York, NY 10022
Telephone: (212) 355-3000

Lunch will be served at 12:00 p.m. Presentations will begin at 12:30 p.m.

Registration is required as space is limited.

To obtain venue details and register please contact Samantha Alphonso at Financial Relations Board (212-827-3746 or E-mail: salphonso@frbir.com) or contact her with any related questions.

Company Management Scheduled to Present:

• Thomas Curran, Chairman of the Board
• Tim Richerson, CEO
• Kenneth Kornman, President and Chief Scientific Officer
• Sir Gordon Duff, Chairman of Interleukin’s Scientific Advisory Board and Florey Professor of Molecular Medicine, University of Sheffield, UK
• Strategic partners who will provide in-depth information about ILI products and their global market potential

Interleukin Genetics, Inc. is focused on developing, acquiring, and commercializing personalized health products that can help individuals improve and maintain their health through preventive measures. It uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. The Company also develops and markets nutritional and OTCeutical® products. Interleukin has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. In addition, through its Alan James Group subsidiary which it acquired in August 2006, Interleukin sells its nutritional product brands, including Ginkoba®, Ginsana®, and Venastat® through the nation’s largest food, drug and mass retailers. The Company’s current development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as its new proprietary OTCeuticals for distribution through Alan James Group. The Company expects that these programs will also lead to the personalized selection of nutritional products, and provide consumers and healthcare professionals with better preventive product alternatives. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

 

06/12/2007
The Waldorf Astoria
New York
NY